Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

Biochemical Pharmacology

Volumn 157, Issue , 2018, Pages 67-84

  Aymerich, Maria S ^a,b   Aso, Ester ^c,d   Abellanas, Miguel A ^a   Tolon, Rosa M ^e   Ramos, Jose A ^d,f,g   Ferrer, Isidre ^c,d   Romero, Julian ^e   Fernández Ruiz, Javier ^d,f,g  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Recinto de Complejo Hospitalario de Navarra   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e UNIVERSIDAD FRANCISCO DE VITORIA   (Spain)

^f SCHOOL OF MEDICINE   (Spain)

^g INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

Author keywords

Cannabinoid receptors; Cannabinoids; Endocannabinoid system; Neurodegenerative diseases; Neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN; CANNABINOID; ENDOCANNABINOID; TAU PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; CHRONIC DISEASE; METABOLISM; MOUSE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CANNABINOIDS; CHRONIC DISEASE; ENDOCANNABINOIDS; HUMANS; HUNTINGTON DISEASE; MICE; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 85052160389     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2018.08.016     Document Type: Review

References (264)

1. Saxena, S., Caroni, P., Selective neuronal vulnerability in neurodegenerative diseases from stressor thresholds to degeneration. Neuron 71 (2011), 35–48, 10.1016/j.neuron.2011.06.031.
2. López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., The hallmarks of aging. Cell 153 (2013), 1194–1217, 10.1016/j.cell.2013.05.039.
3. Cummings, J., Disease modification and Neuroprotection in neurodegenerative disorders. Transl. Neurodegener., 6, 2017, 25, 10.1186/s40035-017-0096-2.
4. Kovacs, G.G., Adle-Biassette, H., Milenkovic, I., Cipriani, S., van Scheppingen, J., Aronica, E., Linking pathways in the developing and aging brain with neurodegeneration. Neuroscience 269 (2014), 152–172, 10.1016/j.neuroscience.2014.03.045.
5. Di Marzo, V., Stella, N., Zimmer, A., Endocannabinoid signalling and the deteriorating brain. Nat. Rev. Neurosci. 16 (2015), 30–42, 10.1038/nrn3876.
6. Fernández-Ruiz, J., The biomedical challenge of neurodegenerative disorders an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. Br. J. Pharmacol., 2018, 10.1111/bph.14382.
7. Pacher, P., The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58 (2006), 389–462, 10.1124/pr.58.3.2.
8. Bloom, G.S., Amyloid-β and Tau. JAMA Neurol., 71, 2014, 505, 10.1001/jamaneurol.2013.5847.
9. Li, Y., Establishment of experimental models for Alzheimer's disease research. Int. J. Neurosci. 123 (2013), 823–831, 10.3109/00207454.2013.804821.
10. Ferrer, I., Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog. Neurobiol. 97 (2012), 38–51, 10.1016/j.pneurobio.2012.03.005.
11. Selkoe, D.J., Preventing Alzheimer's disease. Science 337 (2012), 1488–1492, 10.1126/science.1228541.
12. Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., Hughes, A., Jacoby, R., Jones, R., Jones, R., McKeith, I., Macharouthu, A., O'Brien, J., Passmore, P., Sheehan, B., Juszczak, E., Katona, C., Hills, R., Knapp, M., Ballard, C., Brown, R., Banerjee, S., Onions, C., Griffin, M., Adams, J., Gray, R., Johnson, T., Bentham, P., Phillips, P., Donepezil and memantine for moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 366 (2012), 893–903, 10.1056/NEJMoa1106668.
13. Hensley, K., Neuroinflammation in Alzheimer's disease mechanisms, pathologic consequences, and potential for therapeutic manipulation. J. Alzheimers. Dis. 21 (2010), 1–14, 10.3233/JAD-2010-1414.
14. Fernández-Ruiz, J., Romero, J., Ramos, J.A., endocannabinoids and neurodegenerative disorders Parkinson's disease, Huntington's chorea, Alzheimer's disease, and others. Handb. Exp. Pharmacol., 2015, 233–259, 10.1007/978-3-319-20825-1_8.
15. Westlake, T.M., Howlett, A.C., Bonner, T.I., Matsuda, L.A., Herkenham, M., Cannabinoid receptor binding and messenger RNA expression in human brain an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63 (1994), 637–652.
16. Lee, J.H., Agacinski, G., Williams, J.H., Wilcock, G.K., Esiri, M.M., Francis, P.T., Wong, P.T.-H., Chen, C.P., Lai, M.K.P., Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochem. Int. 57 (2010), 985–989, 10.1016/j.neuint.2010.10.010.
17. Ahmad, R., Goffin, K., Van den Stock, J., De Winter, F.-L., Cleeren, E., Bormans, G., Tournoy, J., Persoons, P., Van Laere, K., Vandenbulcke, M., In vivo type 1 cannabinoid receptor availability in Alzheimer's disease. Eur. Neuropsychopharmacol. 24 (2014), 242–250, 10.1016/j.euroneuro.2013.10.002.
18. Manuel, I., González de San Román, E., Giralt, M.T., Ferrer, I., Rodríguez-Puertas, R., Type-1 cannabinoid receptor activity during Alzheimer's disease progression. J. Alzheimers. Dis. 42 (2014), 761–766, 10.3233/JAD-140492.
19. Maroof, N., Ravipati, S., Pardon, M.C., Barrett, D.A., Kendall, D.A., Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the AβPPswe/PS1ΔE9 mouse model of Alzheimer's disease. J. Alzheimers. Dis. 42 (2014), 227–245, 10.3233/JAD-131961.
20. Llorente-Ovejero, A., Manuel, I., Giralt, M.T., Rodríguez-Puertas, R., Increase in cortical endocannabinoid signaling in a rat model of basal forebrain cholinergic dysfunction. Neuroscience 362 (2017), 206–218, 10.1016/j.neuroscience.2017.08.008.
21. Kärkkäine, E., Tanila, H., Laitinen, J.T., Functional autoradiography shows unaltered cannabinoid CB1 receptor signalling in hippocampus and cortex of APP/PS1 transgenic mice. CNS Neurol. Disord. Drug Targets 11 (2012), 1038–1044.
22. Benito, C., Núñez, E., Tolón, R.M., Carrier, E.J., Rábano, A., Hillard, C.J., Romero, J., Cannabinoid CB 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer ’ s disease brains. J. Neurosci. 23 (2003), 11136–11141.
23. Atwood, B.K., Mackie, K., CB2 a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 160 (2010), 467–479, 10.1111/j.1476-5381.2010.00729.x.
24. Ramírez, B.G., Blázquez, C., Gómez del Pulgar, T., Guzmán, M., de Ceballos, M.L., Prevention of Alzheimer's disease pathology by cannabinoids neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 (2005), 1904–1913, 10.1523/JNEUROSCI.4540-04.2005.
25. Savonenko, A.V., Melnikova, T., Wang, Y., Ravert, H., Gao, Y., Koppel, J., Lee, D., Pletnikova, O., Cho, E., Sayyida, N., Hiatt, A., Troncoso, J., Davies, P., Dannals, R.F., Pomper, M.G., Horti, A.G., Cannabinoid CB2 receptors in a mouse model of Aβ amyloidosis immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS One, 10, 2015, 10.1371/journal.pone.0129618 e0129618.
26. Ahmad, R., Postnov, A., Bormans, G., Versijpt, J., Vandenbulcke, M., Van Laere, K., Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging. 43 (2016), 2219–2227, 10.1007/s00259-016-3457-7.
27. López, A., Aparicio, N., Pazos, M.R., Grande, T., Barreda-Manso, M.A., Benito-Cuesta, I., Vázquez, C., Amores, M., Ruiz-Pérez, G., García-García, E., Beatka, M., Tolon, R.M., Dittel, B.N., Hillard, C.J., Cannabinoid CB2 receptors in mouse brain relevance for Alzheimeŕs disease. J. Neuroinflammation., 15, 2018, 158.
28. Chen, R., Zhang, J., Fan, N., Teng, Z.-Q., Wu, Y., Yang, H., Tang, Y.-P., Sun, H., Song, Y., Chen, C., Δ9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling. Cell 155 (2013), 1154–1165, 10.1016/j.cell.2013.10.042.
29. Vázquez, C., Tolón, R.M., Grande, M.T., Caraza, M., Moreno, M., Koester, E.C., Villaescusa, B., Ruiz-Valdepeñas, L., Fernández-Sánchez, F.J., Cravatt, B.F., Hillard, C.J., Romero, J., Endocannabinoid regulation of amyloid-induced neuroinflammation. Neurobiol. Aging. 36 (2015), 3008–3019, 10.1016/j.neurobiolaging.2015.08.003.
30. Jung, K.-M., Astarita, G., Yasar, S., Vasilevko, V., Cribbs, D.H., Head, E., Cotman, C.W., Piomelli, D., An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol. Aging. 33 (2012), 1522–1532, 10.1016/j.neurobiolaging.2011.03.012.
31. Mulder, J., Zilberter, M., Pasquaré S.J., Alpár, A., Schulte, G., Ferreira, S.G., Köfalvi, A., Martín-Moreno, A.M., Keimpema, E., Tanila, H., Watanabe, M., Mackie, K., Hortobágyi, T., de Ceballos, M.L., Harkany, T., Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain. 134 (2011), 1041–1060, 10.1093/brain/awr046.
32. Koppel, J., Bradshaw, H., Goldberg, T.E., Khalili, H., Marambaud, P., Walker, M.J., Pazos, M., Gordon, M.L., Christen, E., Davies, P., Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance a case-control and cohort study. Lipids Health Dis., 8, 2009, 2, 10.1186/1476-511X-8-2.
33. Altamura, C., Ventriglia, M., Martini, M.G., Montesano, D., Errante, Y., Piscitelli, F., Scrascia, F., Quattrocchi, C., Palazzo, P., Seccia, S., Vernieri, F., Di Marzo, V., Elevation of plasma 2-Arachidonoylglycerol Levels in Alzheimer's disease patients as a potential protective mechanism against neurodegenerative decline. J. Alzheimers. Dis. 46 (2015), 497–506, 10.3233/JAD-142349.
34. D'Addario, C., Di Francesco, A., Arosio, B., Gussago, C., Dell'Osso, B., Bari, M., Galimberti, D., Scarpini, E., Altamura, A.C., Mari, D., Maccarrone, M., Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One, 7, 2012, 10.1371/journal.pone.0039186 e39186.
35. Milton, N.G.N., Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci. Lett. 332 (2002), 127–130.
36. Chen, X., Zhang, J., Chen, C., Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults. Neuroscience 178 (2011), 159–168, 10.1016/j.neuroscience.2011.01.024.
37. Harvey, B.S., Ohlsson, K.S., Mååg, J.L.V., Musgrave, I.F., Smid, S.D., Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Neurotoxicology 33 (2012), 138–146, 10.1016/j.neuro.2011.12.015.
38. Janefjord, E., Mååg, J.L.V., Harvey, B.S., Smid, S.D., Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell. Mol. Neurobiol. 34 (2014), 31–42, 10.1007/s10571-013-9984-x.
39. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., Izzo, A.A., Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J. Neurochem. 89 (2004), 134–141, 10.1111/j.1471-4159.2003.02327.x.
40. Aso, E., Palomer, E., Juvés, S., Maldonado, R., Muñoz, F.J., Ferrer, I., CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice. J. Alzheimers. Dis. 30 (2012), 439–459, 10.3233/JAD-2012-111862.
41. Cao, C., Li, Y., Liu, H., Bai, G., Mayl, J., Lin, X., Sutherland, K., Nabar, N., Cai, J., The potential therapeutic effects of THC on Alzheimer's disease. J. Alzheimers. Dis. 42 (2014), 973–984, 10.3233/JAD-140093.
42. van der Stelt, M., Mazzola, C., Esposito, G., Matias, I., Petrosino, S., De Filippis, D., Micale, V., Steardo, L., Drago, F., Iuvone, T., Di Marzo, V., Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. 63 (2006), 1410–1424, 10.1007/s00018-006-6037-3.
43. Haghani, M., Shabani, M., Javan, M., Motamedi, F., Janahmadi, M., CB1 cannabinoid receptor activation rescues amyloid β-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones. Cell. Physiol. Biochem. 29 (2012), 391–406, 10.1159/000338494.
44. Zhang, R.-S., He, Z., Jin, W.-D., Wang, R., Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ1-42-treated mice. Neurobiol. Learn. Mem. 134 Pt B, 2016, 264–274, 10.1016/j.nlm.2016.07.030.
45. Wu, J., Bie, B., Yang, H., Xu, J.J., Brown, D.L., Naguib, M., Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol. Aging. 34 (2013), 791–804, 10.1016/j.neurobiolaging.2012.06.011.
46. Martín-Moreno, A.M., Reigada, D., Ramírez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, A., de Ceballos, M.L., Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol. Pharmacol. 79 (2011), 964–973, 10.1124/mol.111.071290.
47. Fakhfouri, G., Ahmadiani, A., Rahimian, R., Grolla, A.A., Moradi, F., Haeri, A., WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway. Neuropharmacology 63 (2012), 653–666, 10.1016/j.neuropharm.2012.05.013.
48. Martín-Moreno, A.M., Brera, B., Spuch, C., Carro, E., García-García, L., Delgado, M., Pozo, M.A., Innamorato, N.G., Cuadrado, A., de Ceballos, M.L., Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation., 9, 2012, 8, 10.1186/1742-2094-9-8.
49. Aso, E., Juvés, S., Maldonado, R., Ferrer, I., CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J. Alzheimers. Dis. 35 (2013), 847–858, 10.3233/JAD-130137.
50. Cheng, D., Spiro, A.S., Jenner, A.M., Garner, B., Karl, T., Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. J. Alzheimers. Dis. 42 (2014), 1383–1396, 10.3233/JAD-140921.
51. Cheng, D., Low, J.K., Logge, W., Garner, B., Karl, T., Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1ΔE9 mice. Psychopharmacology 231 (2014), 3009–3017, 10.1007/s00213-014-3478-5.
52. Aso, E., Sánchez-Pla, A., Vegas-Lozano, E., Maldonado, R., Ferrer, I., Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J. Alzheimers. Dis. 43 (2015), 977–991, 10.3233/JAD-141014.
53. Aso, E., Andrés-Benito, P., Ferrer, I., Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model. J. Alzheimers. Dis. 54 (2016), 903–912, 10.3233/JAD-160533.
54. Scuderi, C., Steardo, L., Esposito, G., Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement. Phytother. Res. 28 (2014), 1007–1013, 10.1002/ptr.5095.
55. Tolón, R.M., Núñez, E., Pazos, M.R., Benito, C., Castillo, A.I., Martínez-Orgado, J.A., Romero, J., The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 1283 (2009), 148–154, 10.1016/j.brainres.2009.05.098.
56. Bachmeier, C., Beaulieu-Abdelahad, D., Mullan, M., Paris, D., Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier. Mol. Cell. Neurosci. 56 (2013), 255–262, 10.1016/j.mcn.2013.06.004.
57. Wu, J., Hocevar, M., Foss, J.F., Bie, B., Naguib, M., Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer's disease. Eur. J. Pharmacol. 811 (2017), 12–20, 10.1016/j.ejphar.2017.05.044.
58. Piro, J.R., Benjamin, D.I., Duerr, J.M., Pi, Y., Gonzales, C., Wood, K.M., Schwartz, J.W., Nomura, D.K., Samad, T.A., A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep. 1 (2012), 617–623, 10.1016/j.celrep.2012.05.001.
59. Koppel, J., Vingtdeux, V., Marambaud, P., d'Abramo, C., Jimenez, H., Stauber, M., Friedman, R., Davies, P., CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Mol. Med. 20 (2014), 29–36, 10.2119/molmed.2013.00140.revised.
60. Schmöle, A.-C., Lundt, R., Ternes, S., Albayram, Ö., Ulas, T., Schultze, J.L., Bano, D., Nicotera, P., Alferink, J., Zimmer, A., Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model. Neurobiol. Aging. 36 (2015), 710–719, 10.1016/j.neurobiolaging.2014.09.019.
61. Aso, E., Andrés-Benito, P., Carmona, M., Maldonado, R., Ferrer, I., Cannabinoid receptor 2 Participates in Amyloid-β processing in a mouse model of Alzheimer's Disease but plays a minor role in the therapeutic properties of a cannabis-based medicine. J. Alzheimers. Dis. 51 (2016), 489–500, 10.3233/JAD-150913.
62. Chen, B., Bromley-Brits, K., He, G., Cai, F., Zhang, X., Song, W., Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. Curr. Alzheimer Res. 7 (2010), 255–261.
63. Stumm, C., Hiebel, C., Hanstein, R., Purrio, M., Nagel, H., Conrad, A., Lutz, B., Behl, C., Clement, A.B., Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Neurobiol. Aging. 34 (2013), 2574–2584, 10.1016/j.neurobiolaging.2013.05.027.
64. F.I. Aso E, Andrés-Benito P, Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model, Biochem. Pharmacol. In press (2018).
65. Maccarrone, M., Totaro, A., Leuti, A., Giacovazzo, G., Scipioni, L., Mango, D., Coccurello, R., Nisticò R., Oddi, S., Early alteration of distribution and activity of hippocampal type-1 cannabinoid receptor in Alzheimer's disease-like mice overexpressing the human mutant amyloid precursor protein. Pharmacol. Res. 130 (2018), 366–373, 10.1016/j.phrs.2018.02.009.
66. Esposito, G., De Filippis, D., Carnuccio, R., Izzo, A.A., Iuvone, T., The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J. Mol. Med. (Berl) 84 (2006), 253–258, 10.1007/s00109-005-0025-1.
67. Esposito, G., De Filippis, D., Steardo, L., Scuderi, C., Savani, C., Cuomo, V., Iuvone, T., CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci. Lett. 404 (2006), 342–346, 10.1016/j.neulet.2006.06.012.
68. Fernández-Ruiz, J., Sagredo, O., Pazos, M.R., García, C., Pertwee, R., Mechoulam, R., Martínez-Orgado, J., Cannabidiol for neurodegenerative disorders important new clinical applications for this phytocannabinoid?. Br. J. Clin. Pharmacol. 75 (2013), 323–333, 10.1111/j.1365-2125.2012.04341.x.
69. Straiker, A., Dvorakova, M., Zimmowitch, A., Mackie, K., Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons. Mol. Pharmacol. 94 (2018), 743–748, 10.1124/mol.118.111864.
70. Casarejos, M.J., Perucho, J., Gomez, A., Muñoz, M.P., Fernandez-Estevez, M., Sagredo, O., Fernandez Ruiz, J., Guzman, M., de Yebenes, J.G., Mena, M.A., Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J. Alzheimers. Dis. 35 (2013), 525–539, 10.3233/JAD-130050.
71. Cheng, Y., Dong, Z., Liu, S., β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARγ pathway. Pharmacology 94 (2014), 1–12, 10.1159/000362689.
72. Aso, E., Ferrer, I., CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease. Front. Neurosci., 10, 2016, 243, 10.3389/fnins.2016.00243.
73. Cassano, T., Calcagnini, S., Pace, L., De Marco, F., Romano, A., Gaetani, S., Cannabinoid receptor 2 signaling in neurodegenerative disorders from pathogenesis to a promising therapeutic target. Front. Neurosci., 11, 2017, 30, 10.3389/fnins.2017.00030.
74. Zhang, J., Chen, C., Alleviation of neuropathology by inhibition of monoacylglycerol lipase in APP transgenic mice lacking CB2 receptors. Mol. Neurobiol. 55 (2018), 4802–4810, 10.1007/s12035-017-0689-x.
75. Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y.-P., Teng, Z., Chen, C., Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep. 2 (2012), 1329–1339, 10.1016/j.celrep.2012.09.030.
76. Nomura, D.K., Morrison, B.E., Blankman, J.L., Long, J.Z., Kinsey, S.G., Marcondes, M.C.G., Ward, A.M., Hahn, Y.K., Lichtman, A.H., Conti, B., Cravatt, B.F., Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science (80-.) 334 (2011), 809–813, 10.1126/science.1209200.
77. Murphy, N., Cowley, T.R., Blau, C.W., Dempsey, C.N., Noonan, J., Gowran, A., Tanveer, R., Olango, W.M., Finn, D.P., Campbell, V.A., Lynch, M.A., The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. J. Neuroinflammation., 9, 2012, 79, 10.1186/1742-2094-9-79.
78. Rampa, A., Bartolini, M., Bisi, A., Belluti, F., Gobbi, S., Andrisano, V., Ligresti, A., Di Marzo, V., The first dual ChE/FAAH inhibitors new perspectives for Alzheimer's disease?. ACS Med. Chem. Lett. 3 (2012), 182–186, 10.1021/ml200313p.
79. Montanari, S., Scalvini, L., Bartolini, M., Belluti, F., Gobbi, S., Andrisano, V., Ligresti, A., Di Marzo, V., Rivara, S., Mor, M., Bisi, A., Rampa, A., Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE) Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. J. Med. Chem. 59 (2016), 6387–6406, 10.1021/acs.jmedchem.6b00609.
80. Wang, X., Wang, W., Li, L., Perry, G., Lee, H., Zhu, X., Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim. Biophys. Acta Mol. Basis Dis. 2014 (1842), 1240–1247, 10.1016/j.bbadis.2013.10.015.
81. Lee, H.P., Zhu, X., Casadesus, G., Castellani, R.J., Nunomura, A., Smith, M.A., Lee, H., Perry, G., Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev. Neurother. 10 (2010), 1201–1208, 10.1586/ern.10.74.
82. Esposito, G., Scuderi, C., Valenza, M., Togna, G.I., Latina, V., De Filippis, D., Cipriano, M., Carratù M.R., Iuvone, T., Steardo, L., Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One, 6, 2011, 10.1371/journal.pone.0028668 e28668.
83. Martínez-Pinilla, E., Varani, K., Reyes-Resina, I., Angelats, E., Vincenzi, F., Ferreiro-Vera, C., Oyarzabal, J., Canela, E.I., Lanciego, J.L., Nadal, X., Navarro, G., Borea, P.A., Franco, R., Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front. Pharmacol., 8, 2017, 744, 10.3389/fphar.2017.00744.
84. Sun, S., Hu, F., Wu, J., Zhang, S., Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons. Redox Biol. 11 (2017), 577–585, 10.1016/j.redox.2016.12.029.
85. Valvassori, S.S., Bavaresco, D.V., Scaini, G., Varela, R.B., Streck, E.L., Chagas, M.H., Hallak, J.E.C., Zuardi, A.W., Crippa, J.A., Quevedo, J., Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. Rev. Bras. Psiquiatr. 35 (2013), 380–386, 10.1590/1516-4446-2012-0886.
86. da Silva, V.K., de Freitas, B.S., da Silva Dornelles, A., Nery, L.R., Falavigna, L., Ferreira, R.D.P., Bogo, M.R., Hallak, J.E.C., Zuardi, A.W., Crippa, J.A.S., Schröder, N., Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload implications for neuroprotection. Mol. Neurobiol. 49 (2014), 222–233, 10.1007/s12035-013-8514-7.
87. Singh, N., Hroudová J., Fišar, Z., Cannabinoid-Induced Changes in the Activity of Electron Transport Chain Complexes of Brain Mitochondria. J. Mol. Neurosci. 56 (2015), 926–931, 10.1007/s12031-015-0545-2.
88. Fišar, Z., Singh, N., Hroudová J., Cannabinoid-induced changes in respiration of brain mitochondria. Toxicol. Lett. 231 (2014), 62–71, 10.1016/j.toxlet.2014.09.002.
89. Eubanks, L.M., Rogers, C.J., Beuscher, A.E., Koob, G.F., Olson, A.J., Dickerson, T.J., Janda, K.D., A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol. Pharm. 3 (2006), 773–777, 10.1021/mp060066m.
90. González-Naranjo, P., Pérez-Macias, N., Campillo, N.E., Pérez, C., Arán, V.J., Girón, R., Sánchez-Robles, E., Martín, M.I., Gómez-Cañas, M., García-Arencibia, M., Fernández-Ruiz, J., Páez, J.A., Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. Eur. J. Med. Chem. 73 (2014), 56–72, 10.1016/j.ejmech.2013.11.026.
91. Feigenbaum, J.J., Bergmann, F., Richmond, S.A., Mechoulam, R., Nadler, V., Kloog, Y., Sokolovsky, M., Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. U.S.A. 86 (1989), 9584–9587.
92. Nadler, V., Mechoulam, R., Sokolovsky, M., The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci. Lett. 162 (1993), 43–45.
93. Eshhar, N., Striem, S., Biegon, A., HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. NeuroReport 5 (1993), 237–240.
94. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S.C., Cascio, M.G., Gutiérrez, S.O., van der Stelt, M., López-Rodriguez, M.L., Casanova, E., Schütz, G., Zieglgänsberger, W., Di Marzo, V., Behl, C., Lutz, B., CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003), 84–88, 10.1126/science.1088208.
95. Mackie, K., Hille, B., Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. U.S.A. 89 (1992), 3825–3829.
96. Twitchell, W., Brown, S., Mackie, K., Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78 (1997), 43–50, 10.1152/jn.1997.78.1.43.
97. Zhuang, S.-Y., Bridges, D., Grigorenko, E., McCloud, S., Boon, A., Hampson, R.E., Deadwyler, S.A., Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 48 (2005), 1086–1096, 10.1016/j.neuropharm.2005.01.005.
98. Noonan, J., Tanveer, R., Klompas, A., Gowran, A., McKiernan, J., Campbell, V.A., Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons. J. Biol. Chem. 285 (2010), 38543–38554, 10.1074/jbc.M110.162040.
99. Tanveer, R., Gowran, A., Noonan, J., Keating, S.E., Bowie, A.G., Campbell, V.A., The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-β and in the cortex of aged rats. J. Biol. Chem. 287 (2012), 34709–34721, 10.1074/jbc.M112.350678.
100. Navarro-Dorado, J., Villalba, N., Prieto, D., Brera, B., Martín-Moreno, A.M., Tejerina, T., de Ceballos, M.L., Vascular dysfunction in a transgenic model of Alzheimer's disease effects of CB1R and CB2R cannabinoid agonists. Front. Neurosci., 10, 2016, 422, 10.3389/fnins.2016.00422.
101. Köfalvi, A., Lemos, C., Martín-Moreno, A.M., Pinheiro, B.S., García-García, L., Pozo, M.A., Valério-Fernandes, Â., Beleza, R.O., Agostinho, P., Rodrigues, R.J., Pasquaré S.J., Cunha, R.A., de Ceballos, M.L., Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease. Neuropharmacology 110 (2016), 519–529, 10.1016/j.neuropharm.2016.03.015.
102. Volicer, L., Stelly, M., Morris, J., McLaughlin, J., Volicer, B.J., Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry. 12 (1997), 913–919.
103. Walther, S., Mahlberg, R., Eichmann, U., Kunz, D., Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology 185 (2006), 524–528, 10.1007/s00213-006-0343-1.
104. Passmore, M.J., The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int. J. Geriatr. Psychiatry. 23 (2008), 116–117, 10.1002/gps.1828.
105. van den Elsen, G.A.H., Ahmed, A.I.A., Verkes, R.-J., Kramers, C., Feuth, T., Rosenberg, P.B., van der Marck, M.A., Olde Rikkert, M.G.M., Tetrahydrocannabinol for neuropsychiatric symptoms in dementia. A randomized controlled trial. Neurology 84 (2015), 2338–2346, 10.1212/WNL.0000000000001675.
106. van den Elsen, G.A.H., Ahmed, A.I.A., Verkes, R.-J., Feuth, T., van der Marck, M.A., Olde Rikkert, M.G.M., Tetrahydrocannabinol in behavioral disturbances in dementia. a crossover randomized controlled trial. Am. J. Geriatr. Psychiatry 23 (2015), 1214–1224, 10.1016/j.jagp.2015.07.011.
107. van den Elsen, G.A., Tobben, L., Ahmed, A.I., Verkes, R.J., Kramers, C., Marijnissen, R.M., Olde Rikkert, M.G., van der Marck, M.A., Effects of tetrahydrocannabinol on balance and gait in patients with dementia. A randomised controlled crossover trial. J. Psychopharmacol. 31 (2017), 184–191, 10.1177/0269881116665357.
108. Krishnan, S., Cairns, R., Howard, R., Cannabinoids for the treatment of dementia. Cochrane Database Syst. Rev., 2009, CD007204, 10.1002/14651858.CD007204.pub2.
109. de Lau, L.M.L., Giesbergen, P.C.L.M., de Rijk, M.C., Hofman, A., Koudstaal, P.J., Breteler, M.M.B., Incidence of parkinsonism and Parkinson disease in a general population the Rotterdam Study. Neurology 63 (2004), 1240–1244.
110. Cotzias, G.C., Van Woert, M.H., Schiffer, L.M., Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276 (1967), 374–379, 10.1056/NEJM196702162760703.
111. Bastide, M.F., Meissner, W.G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., Fisone, G., Jon Stoessl, A., Bourdenx, M., Engeln, M., Navailles, S., De Deurwaerdère, P., Ko, W.K.D., Simola, N., Morelli, M., Groc, L., Rodriguez, M.-C., Gurevich, E.V., Quik, M., Morari, M., Mellone, M., Gardoni, F., Tronci, E., Guehl, D., Tison, F., Crossman, A.R., Kang, U.J., Steece-Collier, K., Fox, S., Carta, M., Angela Cenci, M., Bézard, E., Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog. Neurobiol. 132 (2015), 96–168, 10.1016/j.pneurobio.2015.07.002.
112. Le, W., Sayana, P., Jankovic, J., Animal models of parkinson's disease a gateway to therapeutics?. Neurotherapeutics 11 (2014), 92–110, 10.1007/s13311-013-0234-1.
113. Sañudo-Peña, M.C., Tsou, K., Walker, J.M., Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65 (1999), 703–713.
114. Tsou, K., Brown, S., Sañudo-Peña, M., Mackie, K., Walker, J., Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998), 393–411, 10.1016/S0306-4522(97)00436-3.
115. Pisani, V., Madeo, G., Tassone, A., Sciamanna, G., Maccarrone, M., Stanzione, P., Pisani, A., Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov Disord. 26 (2010), 216–222, 10.1002/mds.23457.
116. Giuffrida, A., Parsons, L.H., Kerr, T.M., Rodriguez de Fonseca, F., Navarro, M., Piomelli, D., Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 2 (1999), 358–363, 10.1038/7268.
117. Yin, H.H., Lovinger, D.M., Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc. Natl. Acad. Sci. 103 (2006), 8251–8256, 10.1073/pnas.0510797103.
118. Melis, M., Gessa, G.L., Diana, M., Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog. Neuropsychopharmacol. Biol. Psychiatry 24 (2000), 993–1006.
119. Cheer, J.F., Wassum, K.M., Heien, M.L.A.V., Phillips, P.E.M., Wightman, R.M., Cannabinoids enhance subsecond dopamine release in the nucleus Accumbens of awake rats. J. Neurosci. 24 (2004), 4393–4400, 10.1523/JNEUROSCI.0529-04.2004.
120. Lastres-Becker, I., Molina-Holgado, F., Ramos, J.A., Mechoulam, R., Fernández-Ruiz, J., Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro relevance to Parkinson's disease. Neurobiol. Dis. 19 (2005), 96–107, 10.1016/j.nbd.2004.11.009.
121. Zeng, B.Y., Dass, B., Owen, A., Rose, S., Cannizzaro, C., Tel, B.C., Jenner, P., Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci. Lett. 276 (1999), 71–74.
122. Romero, J., Berrendero, F., Pérez-Rosado, A., Manzanares, J., Rojo, A., Fernández-Ruiz, J.J., de Yebenes, J.G., Ramos, J.A., Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci. 66 (2000), 485–494.
123. Walsh, S., Mnich, K., Mackie, K., Gorman, A.M., Finn, D.P., Dowd, E., Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. Brain Res Bull. 81 (2010), 543–548, 10.1016/j.brainresbull.2010.01.009 S0361-9230(10)00028-6[pii].
124. Lastres-Becker, I., Cebeira, M., de Ceballos, M.L., Zeng, B.Y., Jenner, P., Ramos, J.A., Fernandez-Ruiz, J.J., Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J.Neurosci. 14 (2001), 1827–1832 doi:1812 [pii].
125. Rojo-Bustamante, E., Abellanas, M.A., Clavero, P., Thiolat, M.-L., Li, Q., Luquin, M.R., Bezard, E., Aymerich, M.S., The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. Neurobiol. Dis. 118 (2018), 64–75, 10.1016/j.nbd.2018.06.019.
126. Gubellini, P., Picconi, B., Bari, M., Battista, N., Calabresi, P., Centonze, D., Bernardi, G., Finazzi-Agro, A., Maccarrone, M., Experimental parkinsonism alters endocannabinoid degradation implications for striatal glutamatergic transmission. doi:2002673222/16/6900 [pii] J. Neurosci. 22 (2002), 6900–6907.
127. van der Stelt, M., Fox, S.H., Hill, M., Crossman, A.R., Petrosino, S., Di Marzo, V., Brotchie, J.M., A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 19 (2005), 1140–1142, 10.1096/fj.04-3010fje.
128. Hurley, M.J., Mash, D.C., Jenner, P., Expression of cannabinoid CB 1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J. Neural. Transm. 110 (2003), 1279–1288, 10.1007/s00702-003-0033-7.
129. Navarrete, F., García-Gutiérrez, M.S., Aracil-Fernández, A., Lanciego, J.L., Manzanares, J., Cannabinoid CB1 and CB2 Receptors, and monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with Parkinson's disease. Neurotherapeutics., 2018, 1–11, 10.1007/s13311-018-0603-x.
130. Van Laere, K., Casteels, C., Lunskens, S., Goffin, K., Grachev, I.D., Bormans, G., Vandenberghe, W., Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. NBA., 33, 2012, 10.1016/j.neurobiolaging.2011.02.009 620.e1–620.e8.
131. Pisani, V., Moschella, V., Bari, M., Fezza, F., Galati, S., Bernardi, G., Stanzione, P., Pisani, A., Maccarrone, M., Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Mov Disord. 25 (2010), 920–924, 10.1002/mds.23014.
132. Stella, N., Schweitzer, P., Piomelli, D., A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (1997), 773–778, 10.1038/42015.
133. Gong, J.-P., Onaivi, E.S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P.A., Brusco, A., Uhl, G.R., Cannabinoid CB2 receptors Immunohistochemical localization in rat brain. Brain Res. 1071 (2006), 10–23, 10.1016/j.brainres.2005.11.035.
134. Lanciego, J.L., Barroso-Chinea, P., Rico, A.J., Conte-Perales, L., Callén, L., Roda, E., Gómez-Bautista, V., López, I.P., Lluis, C., Labandeira-García, J.L., Franco, R., Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. J. Psychopharmacol. 25 (2011), 97–104, 10.1177/0269881110367732.
135. Sierra, S., Luquin, N., Rico, A.J., Gómez-Bautista, V., Roda, E., Dopeso-Reyes, I.G., Vázquez, A., Martínez-Pinilla, E., Labandeira-García, J.L., Franco, R., Lanciego, J.L., Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques changes following experimental parkinsonism. Brain Struct. Funct. 220 (2015), 2721–2738, 10.1007/s00429-014-0823-8.
136. García, M.C., Cinquina, V., Palomo-Garo, C., Rábano, A., Fernández-Ruiz, J., Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson's disease. Neurosci. Lett. 587 (2015), 1–4, 10.1016/j.neulet.2014.12.003.
137. Gómez-Gálvez, Y., Palomo-Garo, C., Fernández-Ruiz, J., García, C., Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 64 (2016), 200–208, 10.1016/j.pnpbp.2015.03.017.
138. McGeer, P.L., Itagaki, S., Boyes, B.E., McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38 (1988), 1285–1291.
139. Braak, H., Sastre, M., Del Tredici, K., Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol. 114 (2007), 231–241, 10.1007/s00401-007-0244-3.
140. Concannon, R.M., Okine, B.N., Finn, D.P., Dowd, E., Differential upregulation of the cannabinoid CB(2) receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. Exp. Neurol. 269 (2015), 133–141, 10.1016/j.expneurol.2015.04.007.
141. Concannon, R.M., Okine, B.N., Finn, D.P., Dowd, E., Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease. Exp. Neurol. 283 (2016), 204–212, 10.1016/j.expneurol.2016.06.014.
142. Price, D.A., Martinez, A.A., Seillier, A., Koek, W., Acosta, Y., Fernandez, E., Strong, R., Lutz, B., Marsicano, G., Roberts, J.L., Giuffrida, A., WIN55,212–2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur. J. Neurosci. 29 (2009), 2177–2186, 10.1111/j.1460-9568.2009.06764.x.
143. Fride, E., Perchuk, A., Hall, F.S., Uhl, G.R., Onaivi, E.S., Behavioral methods in cannabinoid research. Methods Mol. Med. 123 (2006), 269–290.
144. Fernandez-Espejo, E., Caraballo, I., de Fonseca, F.R., El Banoua, F., Ferrer, B., Flores, J.A., Galan-Rodriguez, B., Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis. 18 (2005), 591–601, 10.1016/j.nbd.2004.10.015 S0969-9961(04)00267-0 [pii].
145. González, S., Scorticati, C., García-Arencibia, M., de Miguel, R., Ramos, J.A., Fernández-Ruiz, J., Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res. 1073–1074 (2006), 209–219, 10.1016/j.brainres.2005.12.014.
146. Garcia, C., Palomo-Garo, C., Garcia-Arencibia, M., Ramos, J., Pertwee, R., Fernandez-Ruiz, J., Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson's disease. Br J Pharmacol. 163 (2011), 1495–1506, 10.1111/j.1476-5381.2011.01278.x.
147. Meschler, J.P., Howlett, A.C., Madras, B.K., Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacol. 156 (2001), 79–85.
148. Sañudo-Peña, M.C., Patrick, S.L., Khen, S., Patrick, R.L., Tsou, K., Walker, J.M., Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci. Lett. 248 (1998), 171–174.
149. Fernandez-Espejo, E., Caraballo, I., Rodriguez de Fonseca, F., Ferrer, B., El Banoua, F., Flores, J.A., Galan-Rodriguez, B., Experimental parkinsonism alters anandamide precursor synthesis and functional deficits are Improved by AM404 a modulator of endocannabinoid function. Neuropsychopharmacology. 29 (2004), 1134–1142, 10.1038/sj.npp.1300407.
150. van Vliet, S.A.M., Vanwersch, R.A.P., Jongsma, M.J., Olivier, B., Philippens, I.H.C.H.M., Therapeutic effects of Δ9-THC and modafinil in a marmoset Parkinson model. Eur. Neuropsychopharmacol. 18 (2008), 383–389, 10.1016/j.euroneuro.2007.11.003.
151. Brotchie, J.M., CB1 cannabinoid receptor signalling in Parkinson's disease. Curr. Opin. Pharmacol. 3 (2003), 54–61.
152. Cordomí A., Navarro, G., Aymerich, M.S., Franco, R., Structures for G-Protein-coupled receptor tetramers in complex with G proteins. Trends Biochem. Sci. 40 (2015), 548–551, 10.1016/j.tibs.2015.07.007.
153. Garcia-Arencibia, M., Gonzalez, S., de Lago, E., Ramos, J.A., Mechoulam, R., Fernandez-Ruiz, J., Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 1134 (2007), 162–170, 10.1016/j.brainres.2006.11.063.
154. Chung, Y.C., Shin, W.-H., Baek, J.Y., Cho, E.J., Baik, H.H., Kim, S.R., Won, S.-Y., Jin, B.K., CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease. Exp. Mol. Med., 48, 2016, e205, 10.1038/emm.2015.100.
155. Shi, J., Cai, Q., Zhang, J., He, X., Liu, Y., Zhu, R., Jin, L., AM1241 alleviates MPTP-induced Parkinson's disease and promotes the regeneration of DA neurons in PD mice. Oncotarget. 8 (2017), 67837–67850, 10.18632/oncotarget.18871.
156. Javed, H., Azimullah, S., Haque, M.E., Ojha, S.K., Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson's disease. Front. Neurosci., 10, 2016, 321, 10.3389/fnins.2016.00321.
157. Dinh, T.P., Carpenter, D., Leslie, F.M., Freund, T.F., Katona, I., Sensi, S.L., Kathuria, S., Piomelli, D., Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U.S.A. 99 (2002), 10819–10824, 10.1073/pnas.152334899152334899.
158. Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A., Gilula, N.B., Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996), 83–87, 10.1038/384083a0.
159. Fernández-Suárez, D., Celorrio, M., Riezu-Boj, J.I., Ugarte, A., Pacheco, R., González, H., Oyarzabal, J., Hillard, C.J., Franco, R., Aymerich, M.S., The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. Neurobiol. Aging. 35 (2014), 2603–2616, 10.1016/j.neurobiolaging.2014.05.021.
160. Aymerich, M.S., Rojo-Bustamante, E., Molina, C., Celorrio, M., Sanchez-Arias, J.A., Franco, R., Neuroprotective effect of JZL184 in MPP+-Treated SH-SY5Y cells through CB2 receptors. Mol. Neurobiol. 53 (2016), 2312–2319, 10.1007/s12035-015-9213-3.
161. Celorrio, M., Fernández-Suárez, D., Rojo-Bustamante, E., Echeverry-Alzate, V., Ramírez, M.J., Hillard, C.J., López-Moreno, J.A., Maldonado, R., Oyarzábal, J., Franco, R., Aymerich, M.S., Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. Brain. Behav. Immun., 2016, 10.1016/j.bbi.2016.06.010.
162. Kreitzer, A.C., Malenka, R.C., Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445 (2007), 643–647, 10.1038/nature05506.
163. Celorrio, M., Rojo-Bustamante, E., Fernández-Suárez, D., Sáez, E., Estella-Hermoso de Mendoza, A., Müller, C.E., Ramírez, M.J., Oyarzábal, J., Franco, R., Aymerich, M.S., GPR55 A therapeutic target for Parkinson's disease?. Neuropharmacology 125 (2017), 319–332, 10.1016/j.neuropharm.2017.08.017.
164. O'Sullivan, S.E., Cannabinoids go nuclear evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 152 (2007), 576–582, 10.1038/sj.bjp.0707423.
165. Agarwal, S., Yadav, A., Chaturvedi, R.K., Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochem. Biophys. Res. Commun. 483 (2017), 1166–1177, 10.1016/j.bbrc.2016.08.043.
166. Pistis, M., Melis, M., From surface to nuclear receptors the endocannabinoid family extends its assets. Curr. Med. Chem. 17 (2010), 1450–1467.
167. García, C., Gómez-Cañas, M., Burgaz, S., Palomares, B., Gómez-Gálvez, Y., Palomo-Garo, C., Campo, S., Ferrer-Hernández, J., Pavicic, C., Navarrete, C., Luz Bellido, M., García-Arencibia, M., Ruth Pazos, M., Muñoz, E., Fernández-Ruiz, J., Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease possible involvement of different binding sites at the PPARγ receptor. J. Neuroinflammation., 15, 2018, 19, 10.1186/s12974-018-1060-5.
168. Sieradzan, K.A., Fox, S.H., Hill, M., Dick, J.P., Crossman, A.R., Brotchie, J.M., Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease a pilot study. Neurology 57 (2001), 2108–2111, 10.1212/WNL.57.11.2108.
169. Carroll, C.B., Bain, P.G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S.G., Fox, P., Wright, D., Hobart, J., Zajicek, J.P., Cannabis for dyskinesia in Parkinson disease a randomized double-blind crossover study. Neurology 63 (2004), 1245–1250 doi:63/7/1245 [pii].
170. Lotan, I., Treves, T.A., Roditi, Y., Djaldetti, R., Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease an open-label observational study. Clin. Neuropharmacol. 37 (2014), 41–44, 10.1097/WNF.0000000000000016.
171. Frankel, J.P., Hughes, A., Lees, A.J., Stern, G.M., Marijuana for parkinsonian tremor. J. Neurol. Neurosurg. Psychiatry, 53, 1990, 436.
172. Venderová K., Růzicka, E., Vorísek, V., Visnovský P., Survey on cannabis use in Parkinson's disease subjective improvement of motor symptoms. Mov. Disord. 19 (2004), 1102–1106, 10.1002/mds.20111.
173. Finseth, T.A., Hedeman, J.L., Brown, R.P., Johnson, K.I., Binder, M.S., Kluger, B.M., Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado. Evid. Based. Complement. Alternat. Med., 2015, 2015, 874849, 10.1155/2015/874849.
174. Balash, Y., Bar-Lev Schleider, L., Korczyn, A.D., Shabtai, H., Knaani, J., Rosenberg, A., Baruch, Y., Djaldetti, R., Giladi, N., Gurevich, T., Medical Cannabis in parkinson disease. Clin. Neuropharmacol. 40 (2017), 268–272, 10.1097/WNF.0000000000000246.
175. Laprairie, R.B., Bagher, A.M., Kelly, M.E.M., Dupré D.J., Denovan-Wright, E.M., Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J. Biol. Chem. 289 (2014), 24845–24862, 10.1074/jbc.M114.557025.
176. Atwood, B.K., Wager-Miller, J., Haskins, C., Straiker, A., Mackie, K., Functional selectivity in CB(2) cannabinoid receptor signaling and regulation implications for the therapeutic potential of CB(2) ligands. Mol. Pharmacol. 81 (2012), 250–263, 10.1124/mol.111.074013.
177. Carriba, P., Ortiz, O., Patkar, K., Justinova, Z., Stroik, J., Themann, A., Müller, C., Woods, A.S., Hope, B.T., Ciruela, F., Casadó V., Canela, E.I., Lluis, C., Goldberg, S.R., Moratalla, R., Franco, R., Ferré S., Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology. 32 (2007), 2249–2259, 10.1038/sj.npp.1301375.
178. Callén, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortés, A., Mallol, J., Casadó V., Lanciego, J.L., Franco, R., Lluis, C., Canela, E.I., McCormick, P.J., Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J. Biol. Chem. 287 (2012), 20851–20865, 10.1074/jbc.M111.335273.
179. Mesnage, V., Houeto, J.L., Bonnet, A.M., Clavier, I., Arnulf, I., Cattelin, F., Le Fur, G., Damier, P., Welter, M.L., Agid, Y., Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. doi:00002826-200405000-00003 [pii] Clin Neuropharmacol. 27 (2004), 108–110.
180. Jankovic, J., Roos, R.A.C., Chorea associated with Huntington's disease To treat or not to treat?. Mov. Disord. 29 (2014), 1414–1418, 10.1002/mds.25996.
181. Paulsen, J.S., Miller, A.C., Hayes, T., Shaw, E., Cognitive and behavioral changes in Huntington disease before diagnosis. Handb. Clin. Neurol., 2017, 69–91, 10.1016/B978-0-12-801893-4.00006-7.
182. Rüb, U., Seidel, K., Heinsen, H., Vonsattel, J.P., den Dunnen, W.F., Korf, H.W., Huntington's disease (HD) the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol. 26 (2016), 726–740, 10.1111/bpa.12426.
183. Ross, C.A., Kronenbuerger, M., Duan, W., Margolis, R.L., Mechanisms underlying neurodegeneration in Huntington disease applications to novel disease-modifying therapies. Handb. Clin. Neurol. 144 (2017), 15–28, 10.1016/B978-0-12-801893-4.00002-X.
184. Zielonka, D., Mielcarek, M., Landwehrmeyer, G.B., Update on Huntington's disease advances in care and emerging therapeutic options. Parkinsonism Relat. Disord. 21 (2015), 169–178, 10.1016/j.parkreldis.2014.12.013.
185. Zuccato, C., Cattaneo, E., Huntington's disease. Handb. Exp. Pharmacol. 220 (2014), 357–409, 10.1007/978-3-642-45106-5_14.
186. Menalled, L., Brunner, D., Animal models of Huntington's disease for translation to the clinic Best practices. Mov. Disord. 29 (2014), 1375–1390, 10.1002/mds.26006.
187. Sampaio, C., Borowsky, B., Reilmann, R., Clinical trials in Huntington's disease. Interventions in early clinical development and newer methodological approaches. Mov. Disord. 29 (2014), 1419–1428, 10.1002/mds.26021.
188. Kieburtz, K., Reilmann, R., Olanow, C.W., Huntington's disease Current and future therapeutic prospects. Mov. Disord., 2018, 10.1002/mds.27363.
189. Lastres-Becker, I., De Miguel, R., Fernández-Ruiz, J.J., The endocannabinoid system and Huntington's disease. Curr. Drug Targets. CNS Neurol. Disord. 2 (2003), 335–347.
190. Müller-Vahl, K.R., Kolbe, H., Schneider, U., Emrich, H.M., Cannabis in movement disorders. Forsch. Komplementarmed. 6:Suppl 3 (1999), 23–27.
191. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., Schram, K., Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol. Biochem. Behav. 40 (1991), 701–708.
192. Müller-Vahl, K.R., Schneider, U., Emrich, H.M., Nabilone increases choreatic movements in Huntington's disease. Mov. Disord. 14 (1999), 1038–1040.
193. Curtis, A., Rickards, H., Nabilone could treat chorea and irritability in Huntington's disease. J. Neuropsychiatry Clin. Neurosci. 18 (2006), 553–554, 10.1176/jnp.2006.18.4.553.
194. Curtis, A., Mitchell, I., Patel, S., Ives, N., Rickards, H., A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov. Disord. 24 (2009), 2254–2259, 10.1002/mds.22809.
195. López-Sendón Moreno, J.L., García Caldentey, J., Trigo Cubillo, P., Ruiz Romero, C., García Ribas, G., Alonso Arias, M.A.A., García de Yébenes, M.J., Tolón, R.M., Galve-Roperh, I., Sagredo, O., Valdeolivas, S., Resel, E., Ortega-Gutierrez, S., García-Bermejo, M.L., Fernández Ruiz, J., Guzmán, M., García de Yébenes Prous, J., A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. J. Neurol. 263 (2016), 1390–1400, 10.1007/s00415-016-8145-9.
196. Saft, C., von Hein, S.M., Lücke, T., Thiels, C., Peball, M., Djamshidian, A., Heim, B., Seppi, K., Cannabinoids for treatment of dystonia in Huntington's. Disease, J. Huntingtons. Dis., 2018, 1–7, 10.3233/JHD-170283.
197. Glass, M., Dragunow, M., Faull, R.L., The pattern of neurodegeneration in Huntington's disease a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 (2000), 505–519.
198. Lastres-Becker, I., Berrendero, F., Lucas, J.J., Martín-Aparicio, E., Yamamoto, A., Ramos, J.A., Fernández-Ruiz, J.J., Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res. 929 (2002), 236–242.
199. Dowie, M.J., Bradshaw, H.B., Howard, M.L., Nicholson, L.F.B., Faull, R.L.M., Hannan, A.J., Glass, M., Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience 163 (2009), 456–465, 10.1016/j.neuroscience.2009.06.014.
200. Ooms, M., Rietjens, R., Rangarajan, J.R., Vunckx, K., Valdeolivas, S., Maes, F., Himmelreich, U., Fernandez-Ruiz, J., Bormans, G., Van Laere, K., Casteels, C., Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. Neurobiol. Aging. 35 (2014), 2858–2869, 10.1016/j.neurobiolaging.2014.06.010.
201. Pouladi, M.A., Stanek, L.M., Xie, Y., Franciosi, S., Southwell, A.L., Deng, Y., Butland, S., Zhang, W., Cheng, S.H., Shihabuddin, L.S., Hayden, M.R., Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet. 21 (2012), 2219–2232, 10.1093/hmg/dds037.
202. Woodman, B., Butler, R., Landles, C., Lupton, M.K., Tse, J., Hockly, E., Moffitt, H., Sathasivam, K., Bates, G.P., The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 72 (2007), 83–97, 10.1016/j.brainresbull.2006.11.004.
203. Pintor, A., Tebano, M.T., Martire, A., Grieco, R., Galluzzo, M., Scattoni, M.L., Pèzzola, A., Coccurello, R., Felici, F., Cuomo, V., Piomelli, D., Calamandrei, G., Popoli, P., The cannabinoid receptor agonist WIN 55,212–2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 51 (2006), 1004–1012, 10.1016/j.neuropharm.2006.06.013.
204. Blázquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, M.R., Resel, E., Palazuelos, J., Julien, B., Salazar, M., Börner, C., Benito, C., Carrasco, C., Diez-Zaera, M., Paoletti, P., Díaz-Hernández, M., Ruiz, C., Sendtner, M., Lucas, J.J., de Yébenes, J.G., Marsicano, G., Monory, K., Lutz, B., Romero, J., Alberch, J., Ginés, S., Kraus, J., Fernández-Ruiz, J., Galve-Roperh, I., Guzmán, M., Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain. 134 (2011), 119–136, 10.1093/brain/awq278.
205. Laprairie, R.B., Warford, J.R., Hutchings, S., Robertson, G.S., Kelly, M.E.M., Denovan-Wright, E.M., The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients. J. Neuroimmunol. 267 (2014), 61–72, 10.1016/j.jneuroim.2013.12.008.
206. Lastres-Becker, I., Bizat, N., Boyer, F., Hantraye, P., Fernández-Ruiz, J., Brouillet, E., Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. NeuroReport 15 (2004), 2375–2379.
207. Chiodi, V., Uchigashima, M., Beggiato, S., Ferrante, A., Armida, M., Martire, A., Potenza, R.L., Ferraro, L., Tanganelli, S., Watanabe, M., Domenici, M.R., Popoli, P., Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 45 (2012), 983–991, 10.1016/j.nbd.2011.12.017.
208. Chiarlone, A., Bellocchio, L., Blázquez, C., Resel, E., Soria-Gómez, E., Cannich, A., Ferrero, J.J., Sagredo, O., Benito, C., Romero, J., Sánchez-Prieto, J., Lutz, B., Fernández-Ruiz, J., Galve-Roperh, I., Guzmán, M., A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 8257–8262, 10.1073/pnas.1400988111.
209. Fernández-Ruiz, J., The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 156 (2009), 1029–1040, 10.1111/j.1476-5381.2008.00088.x.
210. Ruiz-Calvo, A., Maroto, I.B., Bajo-Grañeras, R., Chiarlone, A., Gaudioso, Á., Ferrero, J.J., Resel, E., Sánchez-Prieto, J., Rodríguez-Navarro, J.A., Marsicano, G., Galve-Roperh, I., Bellocchio, L., Guzmán, M., Pathway-specific control of striatal neuron vulnerability by corticostriatal cannabinoid CB1 receptors. Cereb. Cortex. 28 (2018), 307–322, 10.1093/cercor/bhx285.
211. Sagredo, O., González, S., Aroyo, I., Pazos, M.R., Benito, C., Lastres-Becker, I., Romero, J.P., Tolón, R.M., Mechoulam, R., Brouillet, E., Romero, J., Fernández-Ruiz, J., Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity relevance for Huntington's disease. Glia 57 (2009), 1154–1167, 10.1002/glia.20838.
212. Palazuelos, J., Aguado, T., Pazos, M.R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., Fernández-Ruiz, J., Guzmán, M., Galve-Roperh, I., Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132 (2009), 3152–3164, 10.1093/brain/awp239.
213. Bouchard, J., Truong, J., Bouchard, K., Dunkelberger, D., Desrayaud, S., Moussaoui, S., Tabrizi, S.J., Stella, N., Muchowski, P.J., Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J. Neurosci. 32 (2012), 18259–18268, 10.1523/JNEUROSCI.4008-12.2012.
214. Dowie, M.J., Grimsey, N.L., Hoffman, T., Faull, R.L.M., Glass, M., Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. J. Chem. Neuroanat. 59–60 (2014), 62–71, 10.1016/j.jchemneu.2014.06.004.
215. Lastres-Becker, I., Fezza, F., Cebeira, M., Bisogno, T., Ramos, J.A., Milone, A., Fernández-Ruiz, J., Di Marzo, V., Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. NeuroReport 12 (2001), 2125–2129.
216. Bisogno, T., Martire, A., Petrosino, S., Popoli, P., Di Marzo, V., Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem. Int. 52 (2008), 307–313, 10.1016/j.neuint.2007.06.031.
217. Bari, M., Battista, N., Valenza, M., Mastrangelo, N., Malaponti, M., Catanzaro, G., Centonze, D., Finazzi-Agrò A., Cattaneo, E., Maccarrone, M., In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system. FEBS J. 280 (2013), 3376–3388, 10.1111/febs.12329.
218. Battista, N., Bari, M., Tarditi, A., Mariotti, C., Bachoud-Lévi, A.-C., Zuccato, C., Finazzi-Agrò A., Genitrini, S., Peschanski, M., Di Donato, S., Cattaneo, E., Maccarrone, M., Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol. Dis. 27 (2007), 108–116, 10.1016/j.nbd.2007.04.012.
219. Sagredo, O., Pazos, M.R., Valdeolivas, S., Fernandez-Ruiz, J., Cannabinoids novel medicines for the treatment of Huntington's disease. Recent Pat. CNS Drug Discov. 7 (2012), 41–48.
220. Naydenov, A.V., Sepers, M.D., Swinney, K., Raymond, L.A., Palmiter, R.D., Stella, N., Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice. Neurobiol. Dis. 71 (2014), 140–150, 10.1016/j.nbd.2014.08.009.
221. Mievis, S., Blum, D., Ledent, C., Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol. Dis. 42 (2011), 524–529, 10.1016/j.nbd.2011.03.006.
222. Pietropaolo, S., Bellocchio, L., Ruiz-Calvo, A., Cabanas, M., Du, Z., Guzmán, M., Garret, M., Cho, Y.H., Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease. Neuropharmacology 89 (2015), 368–374, 10.1016/j.neuropharm.2014.07.021.
223. Dowie, M.J., Howard, M.L., Nicholson, L.F.B., Faull, R.L.M., Hannan, A.J., Glass, M., Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience 170 (2010), 324–336, 10.1016/j.neuroscience.2010.06.056.
224. Sagredo, O., Ramos, J.A., Decio, A., Mechoulam, R., Fernández-Ruiz, J., Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur. J. Neurosci. 26 (2007), 843–851, 10.1111/j.1460-9568.2007.05717.x.
225. Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M.L., Muñoz, E., Sagredo, O., Neuroprotective properties of cannabigerol in Huntington's disease studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 12 (2015), 185–199, 10.1007/s13311-014-0304-z.
226. Díaz-Alonso, J., Paraíso-Luna, J., Navarrete, C., Del Río, C., Cantarero, I., Palomares, B., Aguareles, J., Fernández-Ruiz, J., Bellido, M.L., Pollastro, F., Appendino, G., Calzado, M.A., Galve-Roperh, I., Muñoz, E., VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. Sci. Rep., 6, 2016, 29789, 10.1038/srep29789.
227. Valdeolivas, S., Satta, V., Pertwee, R.G., Fernández-Ruiz, J., Sagredo, O., Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease role of CB1 and CB2 receptors. ACS Chem. Neurosci. 3 (2012), 400–406, 10.1021/cn200114w.
228. Sagredo, O., Pazos, M.R., Satta, V., Ramos, J.A., Pertwee, R.G., Fernández-Ruiz, J., Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J. Neurosci. Res. 89 (2011), 1509–1518, 10.1002/jnr.22682.
229. Valdeolivas, S., Sagredo, O., Delgado, M., Pozo, M.A., Fernández-Ruiz, J., Effects of a sativex-like combination of phytocannabinoids on disease progression in R6/2 Mice, an experimental model of Huntington's disease. Int. J. Mol. Sci., 18, 2017, 684, 10.3390/ijms18040684.
230. Consroe, P., Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 5 (1998), 534–551, 10.1006/nbdi.1998.0220.
231. van de Zande, N.A., Massey, T.H., McLauchlan, D., Pryce Roberts, A., Zutt, R., Wardle, M., Payne, G.C., Clenaghan, C., Tijssen, M.A.J., Rosser, A.E., Peall, K.J., Clinical characterization of dystonia in adult patients with Huntington's disease. Eur. J. Neurol. 24 (2017), 1140–1147, 10.1111/ene.13349.
232. Hardiman, O., van den Berg, L.H., Kiernan, M.C., Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7 (2011), 639–649, 10.1038/nrneurol.2011.153.
233. Al-Chalabi, A., Hardiman, O., The epidemiology of ALS a conspiracy of genes, environment and time. Nat. Rev. Neurol. 9 (2013), 617–628, 10.1038/nrneurol.2013.203.
234. Renton, A.E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J.R., Schymick, J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L., Kalimo, H., Paetau, A., Abramzon, Y., Remes, A.M., Kaganovich, A., Scholz, S.W., Duckworth, J., Ding, J., Harmer, D.W., Hernandez, D.G., Johnson, J.O., Mok, K., Ryten, M., Trabzuni, D., Guerreiro, R.J., Orrell, R.W., Neal, J., Murray, A., Pearson, J., Jansen, I.E., Sondervan, D., Seelaar, H., Blake, D., Young, K., Halliwell, N., Callister, J.B., Toulson, G., Richardson, A., Gerhard, A., Snowden, J., Mann, D., Neary, D., Nalls, M.A., Peuralinna, T., Jansson, L., Isoviita, V.-M., Kaivorinne, A.-L., Hölttä-Vuori, M., Ikonen, E., Sulkava, R., Benatar, M., Wuu, J., Chiò A., Restagno, G., Borghero, G., Sabatelli, M., Heckerman, D., Rogaeva, E., Zinman, L., Rothstein, J.D., Sendtner, M., Drepper, C., Eichler, E.E., Alkan, C., Abdullaev, Z., Pack, S.D., Dutra, A., Pak, E., Hardy, J., Singleton, A., Williams, N.M., Heutink, P., Pickering-Brown, S., Morris, H.R., Tienari, P.J., Traynor, B.J., Traynor, B.J., A hexanucleotide repeat expansion in C9ORF72 Is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72 (2011), 257–268, 10.1016/j.neuron.2011.09.010.
235. Gijselinck, I., Cruts, M., Van Broeckhoven, C., The genetics of C9orf72 expansions. Cold Spring Harb. Perspect. Med., 8, 2018, 10.1101/cshperspect.a026757 a026757.
236. Gao, F.-B., Almeida, S., Lopez-Gonzalez, R., Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J. 36 (2017), 2931–2950, 10.15252/embj.201797568.
237. Cruts, M., Gijselinck, I., Van Langenhove, T., van der Zee, J., Van Broeckhoven, C., Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 36 (2013), 450–459, 10.1016/j.tins.2013.04.010.
238. Foran, E., Trotti, D., Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid. Redox Signal. 11 (2009), 1587–1602, 10.1089/ars.2009.2444.
239. Ferraiuolo, L., Kirby, J., Grierson, A.J., Sendtner, M., Shaw, P.J., Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7 (2011), 616–630, 10.1038/nrneurol.2011.152.
240. De Vos, K.J., Hafezparast, M., Neurobiology of axonal transport defects in motor neuron diseases opportunities for translational research?. Neurobiol. Dis. 105 (2017), 283–299, 10.1016/j.nbd.2017.02.004.
241. Van Damme, P., Robberecht, W., Van Den Bosch, L., Modelling amyotrophic lateral sclerosis progress and possibilities. Dis. Model. Mech. 10 (2017), 537–549, 10.1242/dmm.029058.
242. Habib, A.A., Mitsumoto, H., Emerging drugs for amyotrophic lateral sclerosis. Expert Opin. Emerg. Drugs. 16 (2011), 537–558, 10.1517/14728214.2011.604312.
243. Petrov, D., Mansfield, C., Moussy, A., Hermine, O., ALS clinical trials review 20 years of failure. Are we any closer to registering a new treatment?. Front. Aging Neurosci., 9, 2017, 68, 10.3389/fnagi.2017.00068.
244. Carter, G.T., Abood, M.E., Aggarwal, S.K., Weiss, M.D., Cannabis and amyotrophic lateral sclerosis hypothetical and practical applications, and a call for clinical trials. Am. J. Hosp. Palliat. Care. 27 (2010), 347–356, 10.1177/1049909110369531.
245. Rossi, S., Bernardi, G., Centonze, D., The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp. Neurol. 224 (2010), 92–102, 10.1016/j.expneurol.2010.03.030.
246. Witting, A., Weydt, P., Hong, S., Kliot, M., Moller, T., Stella, N., Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem. 89 (2004), 1555–1557, 10.1111/j.1471-4159.2004.02544.x.
247. Bilsland, L.G., Dick, J.R.T., Pryce, G., Petrosino, S., Di Marzo, V., Baker, D., Greensmith, L., Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 20 (2006), 1003–1005, 10.1096/fj.05-4743fje.
248. ® -like combination of phytocannabinoids interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci. Ther. 20 (2014), 809–815, 10.1111/cns.12262.
249. Pasquarelli, N., Engelskirchen, M., Hanselmann, J., Endres, S., Porazik, C., Bayer, H., Buck, E., Karsak, M., Weydt, P., Ferger, B., Witting, A., Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. Neuropharmacology 124 (2017), 157–169, 10.1016/j.neuropharm.2017.03.037.
250. Shoemaker, J.L., Seely, K.A., Reed, R.L., Crow, J.P., Prather, P.L., The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 101 (2007), 87–98, 10.1111/j.1471-4159.2006.04346.x.
251. Espejo-Porras, F., Piscitelli, F., Verde, R., Ramos, J.A., Di Marzo, V., de Lago, E., Fernández-Ruiz, J., Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice relevance for a neuroprotective therapy in TDP-43-related disorders. J. Neuroimmune Pharmacol. 10 (2015), 233–244, 10.1007/s11481-015-9602-4.
252. Fernández-Trapero, M., Espejo-Porras, F., Rodríguez-Cueto, C., Coates, J.R., Pérez-Díaz, C., de Lago, E., Fernández-Ruiz, J., Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Dis. Model. Mech. 10 (2017), 551–558, 10.1242/dmm.028373.
253. Yiangou, Y., Facer, P., Durrenberger, P., Chessell, I.P., Naylor, A., Bountra, C., Banati, R.R., Anand, P., COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol., 6, 2006, 12, 10.1186/1471-2377-6-12.
254. Espejo-Porras, F., Fernández-Ruiz, J., de Lago, E., Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Frontotemporal Degener., 2018, 1–10, 10.1080/21678421.2018.1425454.
255. Zhao, P., Ignacio, S., Beattie, E.C., Abood, M.E., Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice implications for excitotoxicity. Eur. J. Neurosci. 27 (2008), 572–579, 10.1111/j.1460-9568.2008.06041.x.
256. Butovsky, O., Jedrychowski, M.P., Cialic, R., Krasemann, S., Murugaiyan, G., Fanek, Z., Greco, D.J., Wu, P.M., Doykan, C.E., Kiner, O., Lawson, R.J., Frosch, M.P., Pochet, N., El Fatimy, R., Krichevsky, A.M., Gygi, S.P., Lassmann, H., Berry, J., Cudkowicz, M.E., Weiner, H.L., Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann. Neurol. 77 (2015), 75–99, 10.1002/ana.24304.
257. Raman, C., McAllister, S.D., Rizvi, G., Patel, S.G., Moore, D.H., Abood, M.E., Amyotrophic lateral sclerosis delayed disease progression in mice by treatment with a cannabinoid, Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 5 (2004), 33–39, 10.1080/14660820310016813.
258. Weydt, P., Hong, S., Witting, A., Möller, T., Stella, N., Kliot, M., Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 6 (2005), 182–184, 10.1080/14660820510030149.
259. Kim, K., Moore, D.H., Makriyannis, A., Abood, M.E., AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol. 542 (2006), 100–105, 10.1016/j.ejphar.2006.05.025.
260. Espejo-Porras, F., García-Toscano, L., Rodríguez-Cueto, C., Santos-García, I., de Lago, E., Fernandez-Ruiz, J., Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br. J. Pharmacol., 2018, 10.1111/bph.14216.
261. Amtmann, D., Weydt, P., Johnson, K.L., Jensen, M.P., Carter, G.T., Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am. J. Hosp. Palliat. Med. 21 (2004), 95–104, 10.1177/104990910402100206.
262. Weber, M., Goldman, B., Truniger, S., Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis a randomised, double-blind crossover trial. J. Neurol. Neurosurg. Psychiatry. 81 (2010), 1135–1140, 10.1136/jnnp.2009.200642.
263. Joerger, M., Wilkins, J., Fagagnini, S., Baldinger, R., Brenneisen, R., Schneider, U., Goldman, B., Weber, M., Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug Metab. Lett. 6 (2012), 102–108.
264. E. de Lago, M. Moreno-Martet, F. Espejo-Porras, F. Fernández-Ruiz, Endocannabinoids and amyotrophic lateral sclerosis, F. L (Ed.), Cannabinoids Neurol. Ment. Dis., Elsevier, 2015 pp. 99–124.